Navigation Links
Revolutionary drug could be new hope for adrenal cancer patients
Date:9/22/2009

SCOTTSDALE, Ariz. (Sept. 22, 2009) TGen Clinical Research Services at Scottsdale Healthcare today announced the start of a clinical trial for a drug designed to combat adrenocortical carcinoma (ACC), a rare but deadly cancer that attacks the adrenal glands.

TCRS is a strategic alliance between the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.

Other than surgery, the only treatment for ACC is the exacting use of a compound called mitotane, a chemical relative of DDT, which the U.S. banned as an insecticide in 1972.

TCRS clinicians hope the new compound, OSI-906, developed by OSI Pharmaceuticals Inc. of Melville, N.Y., will stop ACC tumor growth perhaps even promote tumor shrinkage without the toxic side effects of current chemotherapies. The trial will focus on patients with inoperable tumors who have relapsed or failed to respond to conventional therapies.

This clinical trial of OSI-906 is expected to last several years and include 135 patients, with 30-40 enrolled at TCRS. As there is no standard therapy available, two-thirds of the patients will receive the drug OSI-906 while one-third receives a placebo. Sites elsewhere in the U.S., as well as in Europe and Australia, are expected to enroll patients over the coming months.

"The trial is major step toward helping patients with ACC, who often face radical surgery as part of their treatment," says Dr. Michael J. Demeure, who will oversee the trial locally. Dr. Demeure is a TGen Senior Investigator and a Scottsdale Healthcare surgeon experienced in removing ACC tumors.

"It's a big operation requiring a large incision because these tumors can be the size of a football. Unfortunately many patients' tumors have spread so we can't remove it all, so new treatments are needed.'' said Dr. Demeure. "This unique partnership between Scottsdale Healthcare and TGen allows us to bring the newest and most promising treatments to pat
'/>"/>

Contact: Keith Jones
kjones@shc.org
480-882-4412
Scottsdale Healthcare
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Old developmental pathways spawn revolutionary evolutionary changes
2. M2SYS Introduces Revolutionary Biometric Artificial Intelligence Technology to Significantly Reduce Fingerprint Software False Reject Rates
3. Revolutionary CO2 maps zoom in on greenhouse gas sources
4. Revolutionary chefs? Not likely, shows physics research
5. Singapore-US scientists first to develop revolutionary microchip that uses 30 times less energy
6. Clemson chemists present revolutionary teaching concepts
7. A revolutionary new model for Alzheimers disease
8. New advance in revolutionary bullet fingerprinting technique
9. Newly created cancer stem cells could aid breast cancer research
10. Obesity and lack of exercise could enhance the risk of pancreatic cancer
11. Finding that 1-in-a-billion that could lead to disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Revolutionary drug could be new hope for adrenal cancer patients
(Date:7/22/2014)... that mutations in prickle genes cause epilepsy, which ... repeated seizures over time. However, the mechanism responsible ... new University of Iowa study, published online July ... Academy of Sciences , reveals a novel pathway ... identified the basic cellular mechanism that goes awry ...
(Date:7/22/2014)... The Carlton Complex fires started on July 14, 2014, by ... Valley. The Carlton Complex consists of four fires: Stokes Fire, ... The Stokes and Gold Hikes fires are now one larger ... the area burning is currently over 243,000 acres in size. ... to the high fire danger. Public and firefighter safety is ...
(Date:7/22/2014)... as the ,1000 Bull Genomes Project, aims to accelerate ... while also improving animal health and welfare. Results of ... whole genomes of 234 individual bulls whose direct descendants ... in the journal Nature Genetics . , According ... to reduce or eliminate hereditary diseases and to improve ...
Breaking Biology News(10 mins):UI study finds potential genetic link between epilepsy and neurodegenerative disorders 2Whole-genome sequencing of bulls in key beef and dairy breeds 2
... loss of limb control in individuals with spinal cord ... the neural pathways between brain and spinal cord, although ... remain functional. An artificial neural connection that bridges the ... potential to ameliorate the functional loss. Yukio Nishimura, ...
... facing unprecedented threat from climate change, overfishing, pollution, ... Florida researcher is helping coordinate national efforts to ... ocean for food, medicine, transportation and recreation, yet ... spanning 70 percent of the Earth,s surface are ...
... 10, 2013) The ongoing dance between a ... evolves. While human adenoviruses typically cause mild infections, recent ... severe, sometime fatal, human infections. Researchers from ... Provincial Laboratory for Public Health, School of Systems Biology, ...
Cached Biology News:Scientists stress need for national marine biodiversity observation network 2Scientists stress need for national marine biodiversity observation network 3
(Date:7/22/2014)... The DNA Spectrum Ancestry ... representation of history, migration, and culture. , Throughout ... family history stories stemming from Europe. His father passionately ... Pictures and 8mm home movies painted an elaborate picture ... and Steve ordered a test from DNA Spectrum to ...
(Date:7/22/2014)... SHENZHEN , Kina, 22. juli 2014 /PRNewswire/ ... et datterselskab af BGI, verdens største genomics-organisation, annoncerede ... exome-sekvenseringstjeneste baseret på Complete Genomics brancheførende platform. ... for at levere patenterede sekvenseringsteknologier med 99,999 % ... blev købt af BGI i 2013. Mere end ...
(Date:7/22/2014)... Hussey Copper , a leader in copper manufacturing ... Pullman Regional Hospital,s conversion of more than 1,100 touch ... at a nominal cost.  This reasonably priced surface kills ... within 2 hours of exposure 1 and will aid ... in its facilities. Pullman Regional Hospital, in ...
(Date:7/22/2014)... Quorum Review IRB, the industry leader in ... trials called Quick Step™ . The offering went live ... research industry’s need for seamless study start-up with a large ... studies planning 50 or more North American investigator sites, as ... site count of 80 or more. Qualifying studies may also ...
Breaking Biology Technology:DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3
... in Second of Two Phase 3 Trials ... - Trial Design Was Reviewed Under Special Protocol Assessment Procedure ... ... SPPI ) today announced today that it has,begun enrolling patients in its second ...
... Prize winner Richard Feynman presented a talk entitled There,s Plenty ... was no physical reason why humans couldn,t manipulate atoms. ... the new atom positions remains. How do you know ... 7, 2007 issue of Science, IBM and Imago have taken ...
... September 11, 2007 - 11:00 a.m. ET; 8:00 a.m. ... /PRNewswire-FirstCall/ - MIGENIX,Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage ... call and webcast on Tuesday,September 11, 2007 at 11:00 ... the first fiscal quarter ended July 31, 2007. An ...
Cached Biology Technology:Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer 2Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer 3Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer 4IBM and Imago find a crucial difficulty in semiconductor device scaling 2MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification 2
... peptide transporter 2 (APT2) ... transporter PSF2) (Peptide supply ... transporter involved in antigen ... Antigen: ...
Raised to arginine vasopressin coupled to bovine thyroglobulin with carbodiimide ....
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: